Ensysce Biosciences (ENSC) FCF Margin (2020 - 2025)
Ensysce Biosciences' (ENSC) quarterly FCF Margin came in at 378.46% in Q3 2025, down 34861.0% year-over-year from N/an in Q3 2024, and down 91.74% quarter-over-quarter from 197.37% in Q2 2025.
Powered by 
Analysis
Ensysce Biosciences (ENSC) FCF Margin (2020 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported FCF Margin for 6 consecutive years, with 378.46% the latest figure, recorded in Q3 2025.
- On a quarterly basis, FCF Margin fell 34861.0% year-over-year to 378.46% in Q3 2025; TTM through Sep 2025 was 156.97%, a 3620.0% increase from a year earlier, with the FY2024 full-year figure at 144.0%, up 33929.0% from the prior year.
- FCF Margin was 378.46% for Q3 2025 at Ensysce Biosciences, down from 197.37% in the prior quarter.
- Over five years, FCF Margin peaked at 29.77% in Q2 2021 and troughed at 2403.54% in Q3 2022.
- A 5-year average of 593.05% and a median of 349.86% in 2023 frame the typical range for FCF Margin.
- Across the five-year window, FCF Margin tumbled 211053 bps in 2022 and surged 188384 bps in 2023, its largest moves.
- Over 5 years, FCF Margin stood at 230.41% in 2021, then advanced by 0 bps to 229.91% in 2022, then tumbled by 52 bps to 349.86% in 2023, then soared by 83 bps to 58.61% in 2024, then plunged by 546 bps to 378.46% in 2025.
- The last three FCF Margin figures came in at 378.46% (Q3 2025), 197.37% (Q2 2025), and 129.37% (Q1 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 28.82% |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 18.33% |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | 26.96% |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | 43.05% |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | 2.01% |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | 25.52% |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 29.58% |
| 9 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn | 26.25% |
| 10 | Ensysce Biosciences | 1.18 Mn | -3.46 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -378.46% |
| Jun 30, 2025 | -197.37% |
| Mar 31, 2025 | -129.37% |
| Dec 31, 2024 | -58.61% |
| Sep 30, 2024 | -29.84% |
| Jun 30, 2024 | -1,270.59% |
| Mar 31, 2024 | -1,114.87% |
| Dec 31, 2023 | -349.86% |
| Sep 30, 2023 | -519.69% |
| Jun 30, 2023 | -633.79% |
| Mar 31, 2023 | -456.78% |
| Dec 31, 2022 | -229.91% |
| Sep 30, 2022 | -2,403.54% |
| Jun 30, 2022 | -2,140.30% |
| Mar 31, 2022 | -569.89% |
| Dec 31, 2021 | -230.41% |
| Sep 30, 2021 | -318.53% |
| Jun 30, 2021 | -29.77% |
| Mar 31, 2021 | -206.38% |
| Dec 31, 2020 | -128.18% |